ImmunoGen Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Boston, MA USA
Total Funding:N/A
Industry:Biotech
Founded:1981
Lead Investor(s):N/A

Estimated Revenue & Financials

  • ImmunoGen's estimated annual revenue is currently $73.8M per year.
  • ImmunoGen received $173.3M in venture funding in June 2018.
  • ImmunoGen's estimated revenue per employee is $155,000

Employee Data

  • ImmunoGen has 476 Employees.
  • ImmunoGen grew their employee count by 7% last year.
  • ImmunoGen currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
#1
$8.7M56-12%N/A-N/A
#2
$8.7M5660%N/A-N/A
#3
$16.4M10614%N/A-N/A
#4
$89.4M577N/AN/A-N/A
#5
$116.9M754N/AN/A-N/A
#6
N/A220N/AN/A-N/A
#7
$15.3M99-17%N/A-N/A
#8
N/A94N/AN/A-N/A
#9
$54.6M352N/AN/A-N/A
#10
$17.2M1119%N/A-N/A
Missing a competitor? Contribute!?
Submit

Targeting a better life for people with cancer is why we get up in the morning. It's not enough to disrupt the progress of someone's cancer; we want to keep cancer from disrupting someone's life. That's why everything we do is about developing the most precise, targeted cancer therapies. We believe this is the best way to get people back to their livesback to living today, tomorrow, and beyond. Because for us, targeting a better now is the only thing that matters. We are a clinical-stage biotechnology company that develops targeted cancer therapeutics using antibody-drug conjugate (ADC) technology. Our lead product candidate, mirvetuximab soravtansine, is in Phase 3 study for FR-positive platinum-resistant ovarian cancer, and Phase 1b/2 testing in combination regimens. Our novel IGN candidates for hematologic malignancies, IMGN779 and IMGN632, are in Phase 1 studies. Learn more about who we are, what we do, and how we do it at www.immunogen.com.

keywords:Biotechnology,Healthcare,Marketing,Pharmaceuticals

476

Number of Employees

$73.8M

Revenue (est)

1

Current Jobs

7%

Employee Growth %

N/A

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

ImmunoGen News

12-Sep-19 - Jennison Associates LLC Has $1.35 Million Stock Holdings in ...

Jennison Associates LLC reduced its position in shares of ImmunoGen, Inc. (NASDAQ:IMGN) by 57.8% in the 2nd quarter, according to the ...

1-Sep-19 - ImmunoGen (IMGN) Up 18.8% Since Last Earnings Report ...

It has been about a month since the las t earnings report for ImmunoGen (IMGN). Shares have added about 18.8% in that time frame, ...

12-Sep-19 - Noticeable Observation for Stock Investors: ImmunoGen (IMGN)

ImmunoGen (IMGN) STOCK PRICE MOVEMENT: VOLATILITY FACTOR: The stock remained 6.76% volatile in recent week and indicated ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
#1
$104.1M5087%N/A-N/A
#2
$96.8M538N/AN/A-N/A
#3
$78.2M539N/AN/A3.6/5N/A
#4
$140.6M560N/AN/A-N/A
#5
$127.6M562N/AN/A-N/A

ImmunoGen Funding

DateAmountRoundLead InvestorsReference
2008-06-24$25.0MUndisclosedZiff Asset Management L.PArticle
2009-06-19$33.0MUndisclosedOppenheimer and Co IncArticle
2012-07-13$100.0MUndisclosedArticle
2016-06-15$115.0MUndisclosedArticle
2017-06-05$30.0MUndisclosedSanofiArticle
2017-10-06$UndisclosedUndisclosedJefferiesArticle
2018-06-08$173.3MUndisclosedJ.P. Morgan Securities LLCArticle

ImmunoGen Executive Hires

DateNameTitleReference
2003-11-25Virginia LaveryInterim CFOArticle
2004-07-07Robert J FramVP Clinical DevelopmentArticle
2004-10-26Christopher U. MisslingChief Financial OfficerArticle
2007-10-04Craig BarrowsVP General CounselArticle
2007-11-28John TagliamonteVP Business DevelopmentArticle
2008-08-04Daniel JuniusPresident/COOArticle
2008-11-11James J. O?LearyVP/Chief Medical OfficerArticle
2009-01-12Gregory PerrySVP/CFOArticle
2009-08-18Peter WilliamsVP Business DevelopmentArticle
2009-12-21Suzanne CaddenVP Regulatory Affairs/QualityArticle
2010-06-23Godfrey AmphlettVPArticle
2011-01-19Theresa WingroveVP Regulatory AffairsArticle
2013-12-31David JohnstonEVP/CFOArticle
2014-02-03Eric GuempelVP Product Strategy/Program Management.Article
2014-02-21Ellie HarrisonVP/Chief Human Resources OfficerArticle
2014-02-21Ellie HarrisonVP/Chief Human Resources OfficerArticle
2014-09-16Sandra E. PooleSVP Technical OperationsArticle
2014-12-23Richard J. GregoryEVP Research/Chief Scientific OfficerArticle
2015-04-02Anna BerkenblitSVP/Chief Medical OfficerArticle
2016-04-27Mark J. EnyedyPresident and CEOArticle
2018-04-26Blaine McKeeExecutive Vice President and Chief Business Officer.Article

ImmunoGen Hiring Plans

DateNumber of EmployeesLocationReference
2016-09-3065Article

ImmunoGen Staff Cuts

DateNumber of EmployeesLocationReference
2018-02-1420MassachusettsArticle